期刊
BIOCONJUGATE CHEMISTRY
卷 33, 期 11, 页码 1973-1982出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.bioconjchem.2c00020
关键词
-
类别
资金
- National Science Foundation Materials Science and Engineering Center award [DMR-1720530, DMR-1120901]
- Pennsylvania Department of Health [HRFF 4100083101]
- National Cancer Institute [U01CA254886, U54-CA193417]
- National Heart Lung and Blood Institute [R01-HL124106]
- National Science Foundation [DGE-1845298]
The expression of CD47 on healthy cells, cancer cells, and engineered particles can inhibit phagocytic clearance by binding SIRP alpha on macrophages. In this study, cyclic nano-self peptides were synthesized to mimic and modulate this CD47-SIRP alpha interaction. These peptides showed high antagonistic activity and could act as soluble antagonists of a major macrophage checkpoint.
CD47 on healthy cells, cancer cells, and even engineered particles can inhibit phagocytic clearance by binding SIRP alpha on macrophages. To mimic and modulate this interaction with peptides that could be used as soluble antagonists or potentially as bioconjugates to surfaces, we made cyclic nano-Self peptides based on the key interaction loop of human CD47. Melanoma cells were studied as a standard preclinical cancer model and were antibody-opsonized to adhere to and activate engulfment by primary mouse macrophages. Phagocytosis in the presence of soluble peptides showed cyclic > wildtype > scrambled activity, with the same trend observed with human cells. Opsonized cells that were not engulfed adhered tightly to macrophages, with opposite trends to phagocytosis. Peptide activity is nonetheless higher in human versus mouse assays, consistent with species differences in CD47-SIRP alpha. Small peptides thus function as soluble antagonists of a major macrophage checkpoint.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据